Company
Every investor coverage indicates participated in a round SYNthesis Med Chem raised.
The transaction that ended SYNthesis Med Chem's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Viva Biotech Holdings | Acquisition | 2020 | $123.6m | Forbes Australia, Synthesis BioVentures |
Companies SYNthesis Med Chem acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Prof Andrew Wilks | Founder | Forbes Australia |
| Prof Andrew Wilks | Founder | Synthesis BioVentures |
Stories naming SYNthesis Med Chem. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Also Forbes Australia
Australian diabetes biotech Verva sold all its IP to two biotechs and entered liquidation with PKF Australia appointed; background recalls early Adipogen backing from Uniseed, QIC BioVentures and GBS Ventures.